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Abstract  
Statistical imputation of genotype data is an important technique for analysis of genome-wide association 
studies (GWAS). We have built a reference dataset to improve imputation accuracy for studies of 
individuals of primarily European descent using genotype data from the Hap1, Omni1, and Omni2.5 
human SNP arrays (Illumina). Our dataset contains 2.5-3.1 million variants for 930 European, 157 Asian, 
and 162 African/African-American individuals.  Imputation accuracy of European data from Hap660 or 
OmniExpress array content, measured by the proportion of variants imputed with R2>0.8, improved by 
34%, 23% and 12% for variants with MAF of 3%, 5% and 10%, respectively, compared to imputation 
using publicly available data from 1,000 Genomes and International HapMap projects.  The improved 
accuracy with the use of the new dataset could increase the power for GWAS by as much as 8% relative 
to genotyping all variants. This reference dataset is available to the scientific community through the 
NCBI dbGaP portal.   Future versions will include additional genotype data as well as non-European 
populations.   
 
 
 
 
 
 
 
	   3	  
 
 
Introduction 
Genome-wide association studies (GWAS) have emerged as a successful strategy for the 
discovery of common single nucleotide polymorphism (SNP) markers associated with human 
diseases/traits1. The decreasing cost of commercial dense SNP arrays has enabled investigators to scan the 
genome and prioritize variants for confirmation of true signals amidst a large number of false positives2. 
Hundreds of different loci in the genome have been conclusively associated with more than 100 distinct 
complex diseases and traits, ushering in a new age of discovery in human genetics3.  
The first generation of commercial genotyping arrays was based on genetic variants annotated by 
the International Human HapMap project4-6 as well as those in the NCBI dbSNP database.   These arrays 
have targeted common SNP markers across the genome with the majority of variants with minor allele 
frequency (MAF) greater than 10%, though a small proportion of content included uncommon variants 
with MAF between 5 and 10%7.  Between the bias due to array content and the larger sample sizes needed 
to detect uncommon variants, it is not surprising that the majority of markers identified in GWAS have 
been common variants.  The proliferation of meta-analyses between existing scans, together with larger 
replication sets, have shifted the focus of the field from the identification of a few regions to the discovery 
of comprehensive sets of common variants associated with one or more human diseases or traits8-11.  
Until recently, genome-wide association studies have been conducted with either the 
“HumanHap” series of Illumina, Inc. or the Affymetrix 6.0, genotyping up to 1,000,000 SNPs. The 1000 
Genome Project has laid the foundation for annotating many more common (MAF > 5%) and uncommon 
SNPs (MAF between 1% and 5%) in multiple continental reference populations4-6.  Since commercial 
vendors have transitioned to new denser content arrays that can genotype up to 5,000,000 SNPs, the lack 
of overlap between commercial arrays will require GWAS investigators to depend upon statistical 
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genotype imputation techniques for analysis across vendor arrays as well as between different generations 
of assays by the same vendor. For instance, Illumina, Inc. has recently discontinued and replaced the 
“HumanHap” assays with a new series of “Omni” assays that contain 720,000-5,000,000 SNPs assays 
with content that is substantially different from the earlier series. Similarly, Affymetrix has released the 
Axiom assay, which allows similar genotyping of millions of SNPs based on population-customized 
content.  
Statistical imputation of genotype data12-15 is an important technique that uses patterns of linkage 
disequilibrium observed in a reference set to computationally predict additional genetic variants in silico. 
Imputed genotypes may be tested for association with phenotypes, but also enable the combining of 
genotype data typed on SNP arrays with different content, as well as the use of methods that are intolerant 
of missing data. The accuracy of genotype imputation depends on the sample size of the reference set, the 
comprehensive nature of the SNP coverage, data quality and the comparability of the reference set to the 
study population(s) with respect to the underlying population substructure16-18. Currently, the most 
popular reference sets are the publicly available International HapMap and 1000 Genomes datasets 4-6. 
While these resources are valuable for imputing a sizeable fraction of common SNPs (MAF > 10%), they 
may not be optimal for imputing data for the next generation of GWAS arrays.  
Since most studies have been conducted on first generation commercial arrays with less dense 
content (e.g., optimizing coverage for SNPs with MAF > 10%), we have developed a resource to enable 
use of older array data to impute new content as well as to enhance the ability to combine studies across 
platforms.  Furthermore, the resource can address the performance of imputation of common and now 
uncommon variants not represented on first generation SNP arrays. The Division of Cancer Epidemiology 
and Genetics (DCEG) at the National Cancer Institute (NCI) has generated a dataset, now deposited in 
dbGaP, which is expected to expand to increase SNP genotype content and to incorporate additional data 
from non-European populations. 
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Results 
The DCEG Imputation Reference Set includes; (1) 728 cancer-free individuals of European 
descent from three large prospectively sampled studies19-22 genotyped on the Illumina Hap1, Omni1, 
Omni2.5 arrays; (2) 98 African-American individuals from the Prostate, Lung, Colon, and Ovary Cancer 
Screening Trial (PLCO) genotyped on Illumina Hap1 and Omni2.5 arrays; and  (3) 74 Chinese 
individuals23 genotyped on the Hap660 and the Omni 2.5 arrays from a study of upper gastrointestinal 
cancer in Shanxi, China (SHNX). We combined our dataset with 349 HapMap samples genotyped on the 
Omni 2.5 array to form a harmonized dataset of approximately 2.8 million autosomal polymorphic SNPs 
in 1,249 subjects after rigorous quality control metrics were applied (Table 1). During the quality control 
process, we removed 90 non-founders and two additional subjects forming related pairs from the HapMap 
set. The relationships and extent of overlapping content among the 2.8 million SNPs and the Illumina 
arrays (as portrayed in the commercial manifests) and 1000 Genomes and HapMap 3 data are shown in 
Figure 1a; the OmniExpress content simulated from 2.8 million SNPs of DCEG Reference Set and the 
content overlapping with 1000 Genomes and HapMap 3 data are shown in Figure 1b.  In the DCEG 
Reference Set, the MAF distribution for the Omni2.5 array is shown per population in Figure 2.  It is 
notable that over 1 million uncommon (or rare) SNPs (MAF < 10%) were observed across different 
populations on the Omni2.5 array; the largest number was observed in Asians while the smallest number 
is in African-Americans. Since the full content of the OmniExpress array is contained within the Omni1 
array and the OmniExpress is less expensive, we have reported our analysis using the OmniExpress 
content only throughout the manuscript.  
We compared the imputation performance of the DCEG Reference Set to the International 
HapMap and 1000 genome reference sets, which were available from the IMPUTE2 website (URL 
below). Our approach to measuring imputation performance is based on the comparison of directly 
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genotyped SNPs and probabilistic imputed genotypes (using both IMPUTE213 and BEAGLE12) using 
subsets of directly genotyped SNPs to simulate data genotyped on two prototypes of Illumina commercial 
arrays used in GWAS studies (Hap660 and OmniExpress).  We investigated the utility of the DCEG 
Reference Set by comparing imputation accuracy with that of the publicly available set of HapMap and 
1000 Genomes for SNPs with MAF estimated to be greater than 1%. We assumed that directly genotyped 
SNPs that pass quality control criteria are correct. We measured imputation accuracy between imputed 
SNPs and the previously masked directly genotyped SNPs as the squared-Pearson correlation coefficient 
(R2) using imputed genotype probabilities without censoring and a trend/dosage model (See Methods).   
To address the question of how well imputation can be applied to two commercially available 
SNP arrays, we simulated content for the Illumina Hap660 and OmniExpress arrays. Imputation was 
performed with the IMPUTE2 program with three reference data sets:  (1) DCEG reference set (all 
samples excluding those used for the simulated Illumina datasets); (2) 1000 Genomes project June 2010 
release and HapMap 3 release 213; and (3) the combination of the DCEG reference set and the 1000 
Genomes/HapMap 3 data sets. The reference sets included the 2.8 million SNPs genotyped as part of this 
dataset and/or the 7.8 million SNPs available from the 1000 Genomes project and HapMap 3 release. 
Accuracy was specifically assessed using the subset of 2 million SNPs with MAF > 1%.   
Across the spectrum of MAFs for Illumina Hap660 and OmniExpress, we observed substantial 
improvement in imputation accuracy when using our reference panel compared to the combination of 
1000 Genomes and HapMap data.  We randomly selected 60 samples of European ancestry and imputed 
to the full set of 2.8 million SNPs, out of which 2 million SNPs with MAF > 1% were applicable for the 
evaluation of imputation performance (Figure 3 and also more detailed R2 distribution by MAF is shown 
in Figure 4). Accuracy in the European data from Hap660 or OmniExpress array content, measured by the 
proportion of variants imputed with R2>0.8, improved by 34%, 23% and 12% for variants with MAF of 
3%, 5% and 10%, respectively. For the combined reference from DCEG, 1000 Genomes, and HapMap 3 
data we observed slightly lower performance when imputing from the OmniExpress content to the full set 
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and when combined, we observed no appreciable improvement (Figure 5).  We achieved similar results 
for all of these analyses using both the IMPUTE2 and BEAGLE imputation programs12. 
We suspected that the matching of populations between inference and reference sets could be an 
important factor in overall accuracy. We explored different European populations or US-based cohort 
studies with samples of European ancestry to assess the utility of the new DCEG reference set.  The 
analysis imputed samples of European ancestry from the PLCO study based on an American prospective 
cohort the Cancer Prevention Study-II of the American Cancer Society (CPSII), a Finnish clinical trial, 
the Alpha Tocopherol Beta Carotene Cancer Prevention Study (ATBC), and the European HapMap 
samples (CEU+TSI) respectively. For each, the population substructure was evaluated by principal 
components analysis (Figure 6).  Similar imputation performance was observed for each of the three 
references sets for SNPs > 10% (Figure 7); below this threshold, ATBC, performs surprisingly well for 
such a ‘mismatched’ subpopulation of the same continental origin. For common variants, performance is 
excellent even when population substructure exists, which suggests that for common variants, a reference 
set of sufficient size can adequately predict common SNPs when there is a discrepancy in population 
genetics history. In turn, this confirms the practical adaptation of this approach for many published 
imputation-based studies of European ancestry, in which the reference and inference sets for common 
SNPs differ. Since the accuracy of imputation is also based on sample size, we observed a gradual 
improvement in accuracy as sample size increased from 50 to 800 (Figure 8). Moreover, the effect was 
more pronounced for uncommon SNPs between 5 and 10%, whereas for SNPs above 10% the effect on 
the performance was less notable. The presumed return on investment for SNPs with lower MAF begins 
to diminish even at sample sizes of 600 and 800, an asymptotic behavior explored elsewhere 24.  
Although the current build of the DCEG reference Set is primarily intended for use in European 
populations, we tested the accuracy of imputing OmniExpress data on an African-American set from the 
Multi-Ethnic Cohort (MEC) study 25. Accuracy was less optimal for African Americans, but still superior 
to the publicly available reference data. As seen in Figure 9, there was an improvement in performance 
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for SNPs above 3-5% when the reference set included 98 African-American samples from PLCO and the 
HapMap YRI samples. It is also notable that the performance was better for the combined set than with 
only the African Americans in PLCO (Figure 9). For the two sets, the STRUCTURE plot shows a 
comparable distribution of admixture coefficients for the African-Americans along the axis between EUR 
and AFR (Figure 10). A comparison of the overall imputed SNPs (~2 million when using our reference 
set versus 1.38 million derived from 1000 Genome plus HapMap3) indicates an advantage of the DCEG 
Reference Set with MAF > 3%.  The R2 curve crossed over at 3% in MAF, which could be due to a 
substantial proportion of Omni2.5 SNPs with MAF < 3% that had to be imputed when using the DCEG 
set compared to the combined 1000 Genomes and HapMap set (which included more SNPs < 3% in 
total). When the common set of 1.38 million SNPs is compared, the performance improvement is 
consistent across all ranges of MAF, which was not clearly observed in the European populations (Figure 
3). Additional studies are needed to investigate these observations for African-Americans and perhaps 
other admixed populations that also include a substantial European contribution.  
We compared estimates of power to detect associations in GWAS when SNPs are imputed and 
when they are directly genotyped. With imputation based on the DCEG reference set and 1000 
Genomes/HapMap 3, a GWAS can be expected to detect 92.9% and 84.7%, respectively, of those 
associations discovered by direct genotyping when using the Hap660. The relative power from the DCEG 
reference set and 1000 Genomes/HapMap 3 were 93.9% and 86.2%, respectively, when using the 
OmniExpress based on the model of Park et al.10. These results suggest that new reference set improves 
the power for GWAS by a small, but noticeable, margin.  
	   9	  
 
Discussion 
 In this report we show that a new public resource, the DCEG Reference set, performs better than 
the standard reference data sets, 1000 Genome Project and HapMap 3, for the imputation of common and 
uncommon SNPs, particularly in populations of European background. The improvement in imputation is 
evident in both forward and backward scenarios, namely from the earlier generation arrays to more dense 
arrays and for complementary arrays. Our data suggest that there are distinct advantages for the use of 
genotyped data compared to low pass sequence coverage with respect to the accuracy of imputation, 
which has implications for efficient GWAS studies. While low pass sequencing data may capture more 
variants, the cumulative effects of both higher false-positive and -negative rates may have a suboptimal 
effect on the accuracy of imputation of common and uncommon SNPs. Still, we show that there are 
advantages to imputation using a dataset with validated assays.  
Our data set is particularly useful for investigators to conduct GWAS with a hybrid of data 
generated across arrays or between distinct generations of the same vendor (Hap660 and OmniExpress) 
using genotype imputation techniques to discover promising regions that will require confirmation in 
follow-up studies2. Since many GWAS share cases and controls, the use of our dataset should facilitate 
the approach of shared controls of similar or comparable population background, perhaps even across 
platforms on economic and genetic grounds.  
 Since imputation accuracy depends on the similarity in population substructure between reference 
and study populations, we examined the interchangeability of the three similar, but not identical European 
populations. In our analysis of the DCEG Reference Set, we encountered two unexpected and notable 
results. First, we were surprised to observe that for common SNPs, there was little impact of a reference 
population from Finland, clearly mismatched, with two cohorts drawn from across the continental USA 
(e.g., CPSII and PLCO) (Figure 7). This suggests that for common variants a reference set of sufficiently 
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larger size can adequately capture common SNPs when there is a small but real discrepancy in population 
genetics history. This could enable investigators to proceed with imputation without additional 
genotyping in related but not identical populations.  In the second instance, although overall performance 
of imputation was less optimal for African Americans, we observed that a sufficiently large sample set of 
European subjects can improve imputation in African-Americans, beyond the utility of the PLCO African 
American set, suggesting the value of the larger sample size of European subjects (Figure 9). This could 
have an impact on the design of future studies in other populations with distinct substructures. Despite the 
fact that a subset of MAFs may differ, longer haplotypes could still be useful for imputation of common 
and uncommon variants. Although frequencies of variants may differ among population groups and sub-
populations, our findings suggest that genotype imputation is relatively robust to these differences 
provided that a sufficient number of matching haplotypes appear in the reference data. In the future, larger 
sample sizes should be useful to determine imputation performance, particularly across the spectrum of 
lower MAFs.  
We tested imputing OmniExpress data from European individuals with a reference dataset that 
combined the DCEG and 1,000 Genomes and HapMap references and observed no increase in accuracy 
over that was achieved using the DCEG Reference alone.  This finding suggests that there are distinct 
advantages to using SNP array data compared to low pass sequence coverage with respect to the accuracy 
of imputation and has implications for efficient GWAS studies.  One possible explanation is that SNP 
array and low-pass sequence variant data have distinct patterns of non-random errors. While suboptimal 
for imputation, it may also be necessary to preserve these errors when combining directly genotyped and 
imputed data in order to recapitulate the patterns of differential misclassification and perhaps retain 
statistical validity for association testing. Thus, SNP array data should be superior for imputation of 
genotypes obtained from SNP arrays, though not necessarily superior at imputing the true genotypes.  
While low pass sequencing data may capture more variants, the cumulative effects of both higher false-
positive and -negative rates may also decrease imputation accuracy. 
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 In conclusion, our study has shown the utility of the new DCEG Reference Set and its advantage 
for imputation of common and uncommon SNPs, making it a valuable resource for next-generation 
GWAS with denser chips in new populations. In turn, it is likely that even larger sample sizes will be 
needed for reference sets to explore SNPs with MAF at or below 1%. The DCEG Reference set has been 
released to the Database of Genotypes and Phenotypes (dbGaP) as Build 1. We plan to release subsequent 
builds expanding the number of subjects from diverse populations and adding new genotype content from 
the Affymetrix 6.0, Omni5 arrays, and future commercial products.  
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Materials and Methods 
DNA Samples and Other data sources 
906 subjects were chosen from two clinical trials and 2 prospective cohorts, Alpha-Tocopherol, 
Beta-Carotene Cancer Prevention Study (ATBC), Cancer Prevention Study-II of the American Cancer 
Society (CPS II), the Prostate, Lung, Colon and Ovarian Cancer Prevention Trial (PLCO) and the Shanxi 
Upper Gastrointestinal Cancer Genetics Project (SHNX)23,26. These studies are notable because a large 
number of subjects have been scanned with first generation SNP arrays as components of more than a 
dozen multi-stage GWAS of cancer and cancer-related outcomes. All subjects were cancer-free and over 
the age of 55 at last ascertainment. Subjects of European background were selected from ATBC, CPSII 
and PLCO; African Americans from PLCO; and East Asians from SHNX. Illumina, Inc. provided data 
files for 446 Coriell individuals from HapMap3, namely, CEU, TSI, JPT, CHB and YRI populations 
genotyped on Illumina Omni 2.5 array. For 74 SHNX individuals, genotype data were available for the 
Illumina 660 array26 as well as the Omni2.5 M array. 95 African American samples from the Multi Ethnic 
Cohort27-28 were genotyped separately at USC with the Illumina HumanHap1 and the 2.5 arrays as a test 
set to evaluate the performance of the imputation of African American subjects in our reference set which 
includes 98 African American samples from the PLCO.  
Genotyping and quality control 
Genotype analysis of samples from the ATBC, CPSII, PLCO and SHNX studies were conducted 
at the NCI Core Genotyping Facility according to standard operating procedures. For each sample in 
ATBC, CPSII and PLCO, genotyping was attempted on three different Illumina arrays including Hap1, 
Omni1-Quad and Omni 2.5. Scanned intensities were clustered for each separate array per subject and 
genotypes were called using Gentrain2 algorithm within Illumina Genome Studio. 193 duplicates were 
included in the analysis (59, 63, 48, 21 and 2 for ATBC, CPSII, PLCO, Illumina set and SHNX 
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respectively).  An established quality control (QC) process was applied to samples by study (Referred as 
“QC Groups”) to ensure that only high-quality genotypes were retained for the analytic data set. QC 
metrics included completion rates by sample or locus, sample heterozygosity rate and duplicate 
concordance rate and standard thresholds for exclusion of data generated per array were applied. Overall, 
the results of 198 arrays from 153 different subjects were excluded (Table 2 and 3). After sample-level 
QC was completed for each QC Group including data genotyped at Illumina, the average concordance 
rate for the 193 expected duplicates is greater than 99.9%.  Subsequently, genotypes on distinct arrays 
were merged to subject-level. A total of 17 gender-discordant subjects were excluded on the basis of 
discrepancies in the mean heterozygosity for X chromosome SNPs. In addition, 98 PLCO African 
American samples previously genotyped on Hap1 and 74 SHNX samples previously genotyped on 
Hap660 were added in. 
Ancestry was estimated based on a set of informative SNPs29 using GLU struct.admix module; 
the HapMap build 27 CEU, YRI, ASA (JPT+CHB) samples were used as three continental reference 
populations. The detected ancestry is concordant with self-reported ethnicity except for two self-described 
African-American subjects, for whom the data indicate less than 15% non-CEU ancestry, and thus were 
considered to be CEU ancestry for this study (Figure 10).  Identity by descent (IBD) was estimated using 
the GLU qc.ibds module for all pair-wise comparisons to search for both expected and unexpected 
relatedness among the data set.  
We also excluded subjects and loci with discordance rates greater than 1% after merging the 
genotypes generated from different arrays, resulting in exclusion of five subjects (2 ATBC, 1 CPSII and 2 
PLCO). The merged data of array per subject resulted in the exclusion of a number of loci: 9,662 from the 
ATBC, 6,134 from the CPSII and 10,526 from the PLCO data sets. Assays from Illumina Hap1, Omni1-
Quad, Omni2.5 arrays were harmonized based on the locus meta-data of 1000 Genomes June 2010 
release and HapMap 3 release 2. Also excluded are an additional 942 loci with incompatible alleles 
	   14	  
(either matching directly or by reverse complementing) between our data and the public reference data, 
and additional 644 loci duplicated on Illumina arrays.  
Imputation Scenarios 
We chose IMPUTE2  to conduct all analyses because of its speed and the built-in sliding window 
user interface13. We conducted selected analyses with BEAGLE in parallel (using all default 
configuration and the same sliding window) 12. Both programs performed very similarly, with IMPUTE2 
slightly better than Beagle especially for the loci with MAF < 10%.   
We investigated the effect of our new reference set (728 subjects of European ancestry from 
ATBC, CPSII and PLCO) on accuracy for genotyped SNPs with a MAF of > 1% in comparison to the 
1000 Genomes and HapMap 3 dataset. To address the question of how well imputation can be applied to 
first generation SNP arrays, we simulated content for the Hap660 array in what we designate forward 
imputation, namely using the Hap660 data to impute content on the Omni arrays. A backward imputation 
assessed the ability to impute across the new data set using the OmniExpress. For this analysis, we 
randomly selected 60 subjects (20 each from ATBC, CPSII and PLCO), less than 10% of the 653 subjects 
genotyped on all three Illumina arrays to form the inference set of samples. SNP data for the 60 samples 
(20 from ATBC, CPSII and PLCO) were masked except for those in the inference set of loci. Random 
sampling was repeated at least twice more to ensure reproducibility and robustness.  The reference loci 
sets were either the 2.8 million SNPs genotyped as part of this dataset or the 7.8 million SNPs available 
from the 1000 Genomes project June 2010 release and HapMap 3 February 2009 release. Analyses were 
done for:  (1) DCEG reference set (all samples excluding those used as reference); (2) 1000 Genomes 
project and HapMap 3 (downloaded from the IMPUTE2 site: 
http://mathgen.stats.ox.ac.uk/impute/data_download_1000G_pilot_plus_hapmap3.html); and  (3) the 
union of the DCEG reference set and the 1000 Genomes/HapMap 3 data sets. Accuracy was specifically 
assessed using the subset of 2.0 million SNPs with MAF >1%.  In an exploration of the effect of 
population structure on the imputation accuracy, we evaluated imputation from content on Illumina 
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OmniExpress to the Omni 2.5 SNPs using a subset (202 ATBC, 202 CPSII or 202 CEU+TSI) to impute 
genotypes of 255 PLCO samples of European ancestry. For testing the effect of reference size on 
imputation, the overall combined set of 930 samples was used to assess imputation accuracy in 
comparison to subsets (50, 100, 200, 400, 600 and 800 randomly selected samples) against a fixed set of 
100, randomly chosen. In a preliminary exploration of the utility of the data set in other populations, we 
evaluated imputation in 94 African Americans drawn from the Multi-Ethnic Cohort, using the 
OmniExpress content to impute the remaining SNPs on the Omni 2.5.  
The metric, allelic dosage based R2 value, was calculated for each locus by comparing the 
imputed genotype dosage with the actual assayed genotypes for the inference set.  Dosage R2 is a 
convenient measure of imputation accuracy since its inverse is related to the decrease in power for case-
control association tests.  Another advantage to this measure is that it is applicable to low frequency 
variants, where simpler genotype concordance based measurements become increasingly insensitive.  For 
example, a SNP with a minor allele frequency of 1% achieves a 99% concordance rate by assigning all 
genotypes to homozygous major allele. In our comparisons, the focus is on GWAS study power rather 
than purely on imputation accuracy; consequently, directly genotyped SNPs within the Hap660 and 
OmniExpress subsets are assigned a squared-correlation coefficient R2=1. The curve of R2 > 0.8 for each 
MAF bin is represented in scatter plots. 
Power Estimate 
Power calculations assumed a case/control study with the 10,000 individuals divided equally 
between the two groups.  Associations were assumed to be tested by the score statistic. For SNP j, under 
the null hypothesis of no association, we assumed the test statistic, Sj, was distributed according to a 
noncentral chi-square distribution with 1df. Let tα be 1-10-7 quantile for this distribution. For SNP j, under 
the alternative hypothesis, we assumed that Sj was distributed according to a noncentral chi-square 
distribution,χ2 ηj, with noncentrality parameter ηj and 1 df. The potential power for SNP j is the P(χ2 ηj > 
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tα) . The estimated power for a GWAS is the average of the potential power across all SNPs. To calculate 
ηj, we assumed that disease risk followed an additive genetic model and randomly selected an OR based 
on the distribution described in Park et al 10. When calculating the power for SNP j in the scenario using 
imputation, the value of ηj presuming direct genotyping needed to be multiplied by R2j for those SNPs not 
on the Hap660 or OmniExpress. 
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Figure legends 
Figure 1. Loci included in the analysis of the imputation reference set.   
a) The DCEG Reference Set consists primarily of assays on three commercial arrays totaling ~2.8 
million autosomal polymorphic loci that passed rigorous QC criteria. Note that Hap660 is entirely 
nested within Hap1 except for 14 assays (not depicted). Numbers are in 1,000 units of SNPs. 
b) Approximately 700,000 OmniExpress assays (yellow) were simulated from the DCEG Reference Set 
(blue), of which 683,000 loci exist in the 1000 Genome + HapMap3 except for 22,000 loci. 
Imputation performance using either reference set was compared in the overlapping loci by both 
reference sets (1,421,000+683,000 = 2,104,000). The 1000 Genomes + HapMap3 reference is from 
the IMPUTE2 website, which includes CEU of the 1000 Genome low-coverage data (June 2010) and 
HapMap3 data (February 2009).   Numbers are in 1,000 units of SNPs. 
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Figure 2. Minor Allele Frequency (MAF) distributions for SNPs on Illumina Omni2.5M array 
across study/populations. 
Figure 3. Imputation accuracy for European-American data with DCEG and public reference set. 
The figure depicts the proportion of SNPs with allelic dosage R2 > 0.8 by MAF, shown on the log scale to 
emphasize differences at smaller values. Solid red depicts imputation of Hap660 data using the DCEG 
Reference Set. Dashed red depicts imputation of Hap660 using the 1000 Genome plus HapMap3 
reference. Solid blue depicts imputation of OmniExpress data using the DCEG Reference Set.  Dashed 
blue depicts imputation of OmniExpress using the 1000 Genome plus HapMap3 reference.  
Figure 4. Imputation accuracy for European-American data with DCEG and public reference set 
(more detailed R2 distribution by MAF). 
The proportion of SNPs with five different allelic dosage R2 ranges for each MAF bin. (a) Impute 
OmniExpress data using 1000 Genomes plus HapMap 3 reference; and (b) Impute OmniExpress data 
using DCEG reference.   
Figure 5. The combination of the DCEG Reference Set with the 1000 Genomes and HapMap 3 
results in no improvement in imputation performance. 
The figure depicts the proportion of SNPs with allelic dosage R2 > 0.8 by MAF, shown on the log scale to 
emphasize differences at smaller values. Solid red depicts imputation of Hap660 data using the DCEG 
Reference Set. Dashed red depicts imputation of Hap660 using the 1000 Genome plus HapMap3 
reference. Solid blue depicts imputation of OmniExpress data using the DCEG Reference Set.  Dashed 
blue depicts imputation of OmniExpress using the 1000 Genome plus HapMap3 reference.  
Figure 6. Principal component analysis of populations in ATBC, CPSII, PLCO and HapMap CEU, 
TSI.  
Figure 7. Imputation accuracy for European-American data with matched and mismatched 
reference sub-populations.  
The proportion of SNPs with allelic dosage R2 > 0.8 by MAF, is shown on the log scale to emphasize 
differences at smaller values.  Each scenario measures accuracy of imputing OmniExpress data for 255 
European-American individuals from the PLCO cohort with the following reference data: (ATBC) 202 
ATBC individuals from Finland; (CPSII) 202 CPSII European-American individuals; (CEU+TSI) 202 
HapMap individuals of European-descent from Utah and Northern Italy. 
Figure 8. Imputation accuracy and size of the reference set.   
The proportion of SNPs with allelic dosage R2 > 0.8 by MAF, is shown on the log scale to emphasize 
differences at smaller values. The same set of randomly chosen 100 samples was used as the inference set 
whereas the reference set varied in size by 50, 100, 200, 400, 600 and 800 respectively.  All scenarios 
were imputing from OmniExpress to the contents of Omni 2.5. 
Figure 9. Imputation accuracy for African-American sample set.   
The proportions of SNPs with allelic dosage R2 > 0.8 by MAF, is shown on the log scale to emphasize 
differences at smaller values. Each scenario measures accuracy of imputing OmniExpress data for 94 
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African-American individuals from the MEC cohort25 with the following reference data for 1.4 M SNPs 
in the 1000 Genome Yoruba and HapMap set; Solid blue corresponds to the DCEG Reference Set, Solid 
red corresponds to the 1000 Genome plus HapMap, Solid green corresponds to the subset only of the 98 
PLCO African Americans in the DCEG Reference Set. The dashed blue corresponds to the set of 2 M 
SNPs with MAF > 1% in the DCEG Reference Set.  
Figure 10. STRUCTURE plot of the DCEG Reference Set and MEC data	  
The analysis was conducted using HapMap CEU+TSI, JPT+CHB and YRI as three continental reference 
sets. The admixture coefficients for ATBC, CPSII, MEC, PLCO African American (PLCO_AA), PLCO 
European American (PLCO_EUR) and SHNX are shown along the edges of the triangle. African 
American samples from both PLCO (black) and MEC (cyan) show similar distribution along the AFR and 
EUR axis.     
 
Table legends 
Table 1. Samples included in the imputation reference set 
Subjects passing quality control metrics for the SNP arrays indicated in the right hand columns. This table 
reports the content of Build 1. 
Table 2. QC exclusion threshold 
 
Table 3. Summary of excluded loci 
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IMPUTE2: http://mathgen.stats.ox.ac.uk/impute/data_download_1000G_pilot_plus_hapmap3.html 
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Table	  1.	  Samples	  included	  in	  DCEG	  Reference	  Set	  
	   Populations	   Illumina	  Array	  
Group 
European 
American 
African 
American African Asian H
ap
66
0 
H
ap
1 
O
m
ni
1 
O
m
ni
2.
5 
ATBC 246     ✓ ✓ ✓ 
CPSII 227     ✓ ✓ ✓ 
PLCO 255     ✓ ✓ ✓ 
PLCO  98    ✓  ✓ 
SHNX    74 ✓   ✓ 
HapMap         
CEU 116       ✓ 
CHB    44    ✓ 
JPT    44    ✓ 
TSI 86       ✓ 
YRI   59     ✓ 
Total 930 98 59 162         
	  
Table	  2.	  QC	  exclusion	  thresholds	  
 
QC group 
allowed sample 
heterozygosity 
max. sample 
missing rate  
max. locus 
missing rate  
ATBC Omni2.5 0.17 - 0.19 0.02 0.05 
ATBC Hap1 0.25 - 0.27 0.03 0.06 
ATBC Omni1 0.24 - 0.27 0.03 0.05 
CPSII Omni2.5 0.17 - 0.20 0.04 0.06 
CPSII Hap1 0.26 - 0.28 0.04 0.06 
CPSII Omni1 0.25 - 0.27 0.04 0.06 
HapMap Omni2.5 0.16 - 0.22 0.01 0.04 
PLCO Omni2.5 0.17 - 0.22 0.04 0.05 
PLCO Hap1 0.25 - 0.28 0.04 0.06 
PLCO Omni1 0.24 - 0.27 0.02 0.05 
SHNX Omni2.5 0.16 - 0.18 0.04 0.06 
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Table	  3.	  Summary	  of	  excluded	  loci	  and	  samples	  
 
  Locus Exclusions  Sample Exclusions 
QC group 
 
Missing counts 
 Hetero-
zygosity Missing counts 
Discordant 
duplicates Total* 
ATBC Omni2.5  20,224  1 6  6 
ATBC Hap1  54,513  5 13   14 
ATBC Omni1  132,017  1 10   11 
CPSII Omni2.5  52,990  7 33  37 
CPSII Hap1  64,691  8 20  25 
CPSII Omni1  148,472  6 20 4 29 
HapMap 
Omni2.5 
 7,551  1 0  1 
PLCO Omni2.5  21,616  2 23  24 
PLCO Hap1  66,124  10 33   35 
PLCO Omni1  135,192  0 12  12 
SHNX Omni2.5  53,971  0 4  4 
* Count of unique samples excluded. Some samples were excluded for both excess heterozygosity and 
missing rates. 
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Figure	  1.	  Loci	  included	  in	  the	  analysis	  of	  the	  imputation	  reference	  set.	  	  	  
(a)	  
	  
(b)	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Figure	  2.	  Minor	  Allele	  Frequency	  (MAF)	  distributions	  for	  SNPs	  on	  Illumina	  
Omni2.5M	  array	  across	  study/populations	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
0	  
0.5	  
1	  
1.5	  
2	  
2.5	  
SN
Ps
	  (m
ill
io
ns
)	  
Monomorphic	  	  	  	   0<MAF<3%	  	  	  	  	   3%≤MAF<5%	  	  	  	  	   5%≤MAF<10%	  	  	  	  	  	  	  	   MAF≥10%	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Figure	  3.	  	  Imputation	  accuracy	  for	  European-­‐American	  data	  with	  DCEG	  and	  
public	  reference	  set	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Figure 4.  Imputation	  accuracy	  for	  European-­‐American	  data	  with	  DCEG	  and	  
public	  reference	  set	  (more	  detailed	  R2	  distribution	  by	  MAF)	  
a) 
 
b) 
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Figure 5.  The	  combination	  of	  the	  DCEG	  Reference	  Set	  with	  the	  1000	  Genomes	  
and	  HapMap	  3	  results	  in	  no	  improvement	  in	  imputation	  performance.	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Figure 6.  Principal component analysis of populations in ATBC, CPSII, 
PLCO and HapMap CEU, TSI.  
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Figure	  7.	  Imputation	  accuracy	  for	  European-­‐American	  data	  with	  matched	  and	  
mismatched	  reference	  sub-­‐populations.	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Figure	  8.	  Imputation	  accuracy	  and	  size	  of	  the	  reference	  set.	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Figure	  9.	  	  Imputation	  accuracy	  for	  an	  African-­‐American	  sample	  set.	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Figure	  10.	  STRUCTURE	  plot	  of	  the	  DCEG	  Reference	  Set	  and	  MEC	  data	  
	  
	  
 
